baber/WOPTO huggingface dataset:
Patent NZ-516914-A (NZ)
Title: Compositions containing COX-2 selective carprofen and derivatives thereof for treating pain and inflammation in dogs
Inventor: LUNDY KRISTIN MARIE
IPC: A61K31/403
Filed: 1998-05-01
Abstract: A chewable formulation containing carprofen, an implant releasing carprofen and a controlled release composition for treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2 : COX-1 activity inhibition is at least 3 : 1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro- a-methyl-9H-carbazole-2-acetic acid.
Patent NZ-525085-A (NZ)
Title: Sporting footwear
Inventor: GERRAND ALAN ROY
IPC: A43B23/00
Filed: 2003-04-01
Abstract: A sports shoe comprising an upper (14) with a toe region (32), the upper (14) having an instep with a pair of longitudinally extending spaced apart ridges, the ridges comprising front ends disposed behind said toe region and rear ends disposed behind said front ends, said toe region (32) being disposed ahead of said front ends, said toe region (32) having a reduced height lower that a height of said ridges, said reduced height facilitating flexibility of said shoe in said toe region (32), wherein said ridges comprise a single component adapted to overlay said upper (14), in which component said ridges are integrally joined above said upper (14), the shoe further comprising fastening means (22) such that said single component is releasably attachable to said upper (14). ( 62) Divided out of 505283
Patent NZ-527968-A (NZ)
Title: Storage vessel
Inventor: GOGGIN BRIAN ANTHONY
IPC: B60K15/00
Filed: 2003-09-01
Abstract: A storage vessel for storing a fluid substance, the storage vessel including a plurality of abutting individually sealed storage chambers, each chamber capable of withstanding super atmospheric pressure, with adjacent chambers forming at least one fluid passageway therebetween. The chambers are formed from a pair of spaced-apart, substantially coterminous, planar panels peripheral joined by a seal. The panels are spaced apart by mutual contact between a plurality of surface features extending laterally from at least one confronting panel surface(s) between adjacent panels. The at least one fluid passageway between adjacent chambers and/or the surface features provides a circuitous fluid path attenuating fluid flow volume between chambers and/or through any failed peripheral seal.
Patent NZ-536054-A (NZ)
Title: Motif-grafted hybrid polypeptides and uses thereof
Inventor: BURTON DENNIS R
IPC: C07K19/00
Filed: 2003-04-08
Abstract: Disclosed is a hybrid polypeptide, comprising: a polypeptide motif that contains at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 residues from a polypeptide associated with the disease of protein aggregation or conformation that, when in the hybrid polypeptide, binds to an aggregating form of the polypeptide or to a disease-associated conformer of the polypeptide; and a scaffold containing at least 10 amino acid residues from a polypeptide other than the polypeptide from which the motif is derived,wherein: the scaffold is selected from among an antibody or fragment thereof, an enzyme or fragment thereof, a fluorescent molecule or fragment thereof and a chromogenic molecule or fragment thereof; the polypeptide associated with the disease of protein aggregation is selected from among a prion, APP, Abeta. a1-antichymotrypsin, tau, non-Abeta component, presenilin 1, presenilin 2, apoE, superoxide dismutase (SOD) and neurofilament, Pick body, p-synuclein, tau in fibrils, amylin, IgGL-chain, transthyretin, procalcitonin, beta2-microglobulin, atrial natriuretic factor, serum amyloid A, ApoAI, gelsolin and Huntington protein; and the polypeptide motif is inserted into the scaffold or is linked to the scaffold. Also disclosed are nucleotides encoding the above polypeptide, vectors comprising the nucleotide and isolated cells comprising the vector. The polypeptides disclosed are particularly useful in detecting isoforms of polypeptides associated with diseases of protein aggregation.
Patent NZ-536757-A (NZ)
Title: Antibodies specific for human CD22 and their therapeuatic and diagnostic uses
Inventor: POPPLEWELL ANDREW GEORGE
IPC: A61K39/395
Filed: 2003-05-02
Abstract: An antibody molecule containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. Also disclosed is a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Also disclosed are the DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases medicated by cells expressing CD22.
Patent NZ-537867-A (NZ)
Title: Method of up-regulating TLP expression in tumor cells using thymosin alpha 1
Inventor: RASI GUIDO
IPC: A61P35/00
Filed: 2003-06-30
Abstract: The present invention provides a method for up-regulating tumor cell antigen expression, comprising administering to the cells an amount of thymalfasin sufficient to increase the expression of TLP relative to that of untreated tumor cells. Also provided are methods for enhancing the sensitivity of a immunodiagnostic or immunotherapeutic method, comprising pre-treating target tumor cells by administering to the cells an amount of thymalfasin sufficient to increase the expression of TLP relative to that of untreated tumor cells, followed by application of the immunodiagnostic or immunotherapeutic method.
Patent NZ-541856-A (NZ)
Title: Kit for pharmaceutical use
Inventor: CAWTHRAY RICHARD JAMES
IPC: A61K31/675
Filed: 2004-03-26
Abstract: A kit for promoting the proper sequential oral administration of a pharmaceutically active ingredient and accompanying nutrients, the kit comprising: (a) at least one unit dose of a pharmaceutical active to be given continuously on a frequency of once a week, twice a week, once every two weeks, twice a month, or once a month; (b) at least one unit dose of a nutrient to be given subsequent to the active dose administration; and (c) a blister card individually and releasably containing the unit doses; wherein the unit doses of pharmaceutical active and nutrient are arranged horizontally or vertically in order of their use across the blister card is useful for aiding in patient understanding and complying with dosage regimens wherein the active ingredient is administered on a continuous frequency other than daily and the nutrient is administered on the days in between the days the active ingredient is administered.
Patent NZ-542241-A (NZ)
Title: Ascorbyl-proline derivatives made by covalently bonding L-ascorbic acid, 6-deoxybromoascorbate or 6-deoxyaminoascorbate to proline or proline moieties
Inventor: NIEDZWIECKI ALEKSANDRA
IPC: A61P17/02
Filed: 2002-08-23
Abstract: Disclosed is a process for producing L-ascorbic acid derivatives, comprising: (a) treating L-ascorbic acid with proline or proline moieties, and (b) isolating the L-ascorbic acid derivatives, wherein the L-ascorbic acid is covalently bound to at least one proline and/or polyproline. The ascorbyl-proline derivatives are used for the manufacture of medicaments for the treatment of damage to skin.
Patent NZ-542247-A (NZ)
Title: Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
Inventor: SAMARITANI FABRIZIO
IPC: A61K9/00
Filed: 2004-04-02
Abstract: Provided is a liquid pharmaceutical composition comprising follicle-stimulating hormone(FSH) or a variant thereof, a surfactant comprising a polyoxypropylene-polyoxyethylene block co-polymer of formula shown in the companying figure , such that the surfactant consists of 70 to 80% of polyoxyethylene, and further comprising a bacteriostatic agent selected from phenol and m-cresol. Further provided are compositions containing in addition or separately luteinizing hormone or a variant thereof. Also provided are corresponding freeze-dried formulations, formulations containing other additives, methods of producing packaged pharmaceutical compositions and manufacturing the formulations.
Patent NZ-551996-A (NZ)
Title: Nano-PCR: Methods and devices for nucleic acid amplification and detection
Inventor: GOEL ANITA
IPC: C12P19/34
Filed: 2005-05-13
Abstract: Disclosed is a method for amplifying a nucleic acid, comprising: (a) contacting one or more template strands of single-stranded nucleic acid with one or more oligonucleotide primers complementary to a portion of the one or more template strands; (b) annealing at least one primer of the one or more primers to the portion of the one or more template strands to which the primer is complimentary; (c) contacting the one or more template strands with a nucleic acid polymerase and at least four different nucleoside triphosphates; (d) extending the at least one annealed primer by the nucleic acid polymerase thereby forming one or more extension products bound to the one or more template strands; (e) separating the one or more extension products from the one or more template strands; and repeating steps (a), (b), (c), (d) and (e) to amplify the nucleic acid, wherein at least one of the one or more extension products in step (e) is used as template strands in a subsequent cycle of steps (a)-(e), wherein for the last cycle, step (e) is optional, and wherein at least one of steps (b) or (d) comprises applying tension to the one or more template strands.
Patent NZ-553281-A (NZ)
Title: NT CNP Peptides and uses thereof
Inventor: RICHARDS ARTHUR MARK
Filed: 2003-06-17
Abstract: A method for assessing skeletal growth of a subject, comprising measuring the level of NT-CNP in a biological sample from the subject, and comparing the level against the mean NT-CNP level from a control population, wherein a significant difference in the measured NT-CNP level outside two standard deviations of the mean control level is indicative of abnormal skeletal growth in a patient not suffering from renal failure. (62) Divided Out of 526526
Patent NZ-553425-A (NZ)
Title: A safety anchor
Inventor: PRIDHAM ANDREW DOUGLAS
Filed: 2007-02-26
Abstract: A safety anchor is disclosed. The safety anchor includes a base portion (30), adapted to be connected to a structural member, an attachment means (24), adapted to be attached to a lanyard line, and a stem (22) between the base portion (30) and the attachment means (24). The stem (22) has a region (26), bounded by at least one shoulder (27) of reduced cross-sectional area compared to the remainder of the stem (22). In the event of a predetermined force or greater applied to the attachment means (24), the stem (22) is adapted to at least initially bend at the region (26) of reduced cross-sectional area.
Patent NZ-565394-A (NZ)
Title: Biologically active peptides comprising PTTKTYFPHF and their uses for non-therapeutically reducing fatigue
Inventor: WONG WAI MING
IPC: A61K38/04
Filed: 2006-07-21
Abstract: Disclosed are non-therapeutic methods of reducing fatigue comprising administering a biologically active peptide having an amino acid sequence comprising or consisting of SEQ ID NO: 1 including modulation of liver glycogen storage and modulation of blood lactic acid level. Further disclosed is are methods of reducing fatigue in healthy subjects comprising administering a biologically active peptide having an amino acid sequence comprising or consisting of SEQ ID NO: 1 including modulation of liver glycogen storage and modulation of blood lactic acid level.
Patent NZ-569210-A (NZ)
Title: Improved operating strategies in filtration processes
Inventor: ZHA FUFANG
IPC: B01D61/54
Filed: 2007-01-12
Abstract: Disclosed is a method for reducing the energy requirements of a membrane filtration system. The method includes the steps of providing a plurality of repeated operation cycles in a membrane filtration system and alternating a value of one or more operating parameters of the system between predetermined values, between repetitions of the operation cycles.
Patent NZ-570198-A (NZ)
Title: Methods and dosage forms for controlled delivery of paliperidone or risperidone
Inventor: YAM NOYMI V
IPC: A61K31/519
Filed: 2003-07-28
Abstract: Disclosed is a dosage form comprising two or more layers, said two or more layers comprising a first layer and a second layer, said first layer comprising paliperidone or a pharmaceutically acceptable salt thereof, and said second layer comprising a polymer and paliperidone or a pharmaceutically acceptable salt thereof; an outer wall surrounding said two or more layers; and an orifice in said outer wall; wherein the ratio of the amount of paliperidone or pharmaceutically acceptable salt thereof in the first layer to the amount of paliperidone or pharmaceutically acceptable salt thereof in the second layer is less than 1.0. (62) Divided Out of 537756
Patent NZ-573378-A (NZ)
Title: Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
Inventor: WOLLIN STEFAN-LUTZ
IPC: A61P11/00
Filed: 2007-07-03
Abstract: A pharmaceutical composition that comprises a PDE4 inhibitor and an HMG-CoA reductase inhibitor. The PDE4 inhibitor is 2-{ 4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl} -acetamide and the HMG-CoA reductase inhibitor is atorvastatin. The composition is used for treating an inflammatory pulmonary disease, which can be asthma, COPD, sclerosis, alveolitits, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension.
Patent NZ-580688-A (NZ)
Title: Method of designing altered antibodies having improved antigen-binding affinity
Inventor: VAN VLIJMEN HERMAN
IPC: G16B15/20
Filed: 2004-07-26
Abstract: Provided is a method of increasing the antigen-binding affinity of an antibody, wherein one or more steps of said method is computer-assisted, the method comprising: (i) determining a spatial representation of an optimal charge distribution of the amino acids of the antibody, with constraints imposed to represent amino acid side chain characteristics, and the associated change in binding free energy of the antibody when bound to an antigen in a solvent; (ii) identifying at least one candidate amino acid residue position of the antibody to be modified to alter the binding free energy of the antibody when bound to the antigen based on a potential gain in electrostatic binding free energy as determined in step (i); (iii) selecting an elected amino acid residue for substitution with a replacement amino acid at said candidate amino acid residue position; (iv) wherein said elected amino acid residue is selected from the group consisting of: (a) a residue that becomes partially buried upon binding; (b) a polar residue that becomes buried upon binding; and ( c) a surface residue on the antibody that is in a region of uncomplimentary potentials; (v) calculating the change in the free energy of binding of the antibody containing the modified amino acid or alteration when bound to the antigen as compared to the antibody without the modified amino acid or alteration when bound to the antigen by modelling in silica, wherein a reduction in the free energy of binding of the antibody containing the modified amino acid or alteration as compared to the antibody without the modified amino acid or alteration indicates an increase in antigen-binding affinity, wherein said step utilizes response continuum modelling in determining electrostatic binding energy; and (vi) substituting the elected amino acid residue at the candidate amino acid residue position with a replacement amino acid which closely matches the constraints imposed in step (i) by introducing a mutation into a DNA molecule encoding the antibody, thereby increasing the antigen-binding affinity of the antibody.
Patent NZ-581995-A (NZ)
Title: Process for increasing the refiner production rate and/or decreasing the specific energy of pulping wood
Inventor: LAURINT MARK EDWARD
IPC: D21B1/02
Filed: 2004-12-03
Abstract: Disclosed is a process for increasing the production rate and/or reducing specific energy of a refiner for a freeness target comprising: (a) applying a carrier/frictionizer solution to an amount of wood chips prior to delivery into a refining area; and (b) delivering the wood chips to a refiner. Also disclosed is a process for reducing specific energy of a refiner for a freeness target comprising: (1) delivering an amount of wood chips to a refiner; and (2) applying a carrier/frictionizer solution to an amount of wood chips in a refining area. (62) Divided Out of 547456
Patent NZ-585471-A (NZ)
Title: Clip assembly for concealed attaching of profiled sheet metal to a roof
Inventor: HEALY CHRISTOPHER LEE
IPC: E04D3/36
Filed: 2010-05-19
Abstract: Disclosed is a clip assembly for concealed securing of sheet metal profiled roofing sheets. The assembly has a base (38) by which the assembly is mountable on a purlin (P) or other support structure, and two elongate clip members (40) separately secured in relation to and projecting from the base. Each clip member, at an end (43) remote from the base, has an end turned portion (39) adapted for locating over and bearing against an upwardly facing surface of a re-entrant ledge (35) defined by the inner face of a side wall (33) of a rib (29) of a roofing sheet. The turned portion of the two clip members is turned oppositely with respect to each other.
Patent NZ-586274-A (NZ)
Title: A tack or drive screw for securing a prosthesis to bone and associated instrumentation and method
Inventor: MORGAN MICKEY
IPC: A61B17/86
Filed: 2008-12-29
Abstract: Disclosed is an assembly for driving a tack into a patient's bone (S) including. The assembly includes an insertion instrument (100) with a cannulated shaft, a tack with a central axis, a head portion and a shaft portion. The tack is inserted down the cannulated shaft. The insertion instrument further comprises a plurality of rollers having a longitudinal axis, each and being arranged with the longitudinal axes parallel to the central axis of the tack. The plurality of rollers circumferentially surrounding and providing axial constraints to the tack inserted through the cannulated shaft. Each of the rollers is a cylindrical member having a helical cutout for receiving at least a portion of the head portion of the tack.
Patent NZ-587255-A (NZ)
Title: Elisa assays using prion-specific peptide reagents
Inventor: PERETZ DAVID
IPC: C07K14/47
Filed: 2006-01-13
Abstract: A peptide reagent that interacts with a pathogenic form of a conformational prion-related disease protein (PrPSc). The peptide reagent comprises at least one peptide consisting of up to 100 amino acids and comprises a sequence selected from SEQ ID NOs: 133-135, 137-241 and 243-260.
Patent NZ-589971-A (NZ)
Title: Emollient composition comprising glycerol, vaseline and liquid paraffin
Inventor: FABRE PIERRE
IPC: A61P17/06
Filed: 2009-05-18
Abstract: A composition for topical use that comprises a combination of glycerol, vaseline and liquid paraffin as an active ingredient, in the form of an oil-in-water or water-in-oil emulsion in which the Vaseline (petroleum jelly) has a drop point between 51 degrees C and 57 degrees C, a consistency between 175 1/10 mm and 195 1/10 mm (cone penetration at 25 degrees C) and a viscosity between 4 cSt and 5 cSt at 100 deg C. Also disclosed is the use of the composition in the manufacture of a medicament for treating dermatitis, ichthyosis and psoriasis.
Patent NZ-598492-A (NZ)
Title: Tubular building structure with hingedly connected platform segment
Inventor: RYHOLL LARS
IPC: E04G11/06
Filed: 2010-09-14
Abstract: 598492 Disclosed is a method of erecting a tubular building structure comprising superposed tube sections each being formed by interconnected axially extending tube segments, such as a telecommunications tower or wind turbine mast, with an internal service platform. The method comprises forming a base for the building structure and at least one tube section extending upwardly there from and forming a further tube section on top of an upper tube section already positioned on the base. The lower parts of the tube segments of the further tube section are fastened to the upper tube section and interconnecting adjacent tube segments so as to form the further tube section. The tube segments comprise flanges along each side of opposite longitudinal sides of the tube segments which flanges extend radially inwardly with respect to a longitudinal axis of the tubular building structure. The tube segments are interconnected by use of bolts or screws via registering holes in the flanges. At least some of the tube segments are provided with platform segments that are hinge-connected and foldable from a collapsed position in which they are positioned close to the tube segment to a position of use in which they extend radially inwardly into the tubular building structure in the mounted position of the tube segments. The platform segments are hinge-connected to the radially inwardly extending flanges.
Patent NZ-602579-A (NZ)
Title: Mitochondrially delivered anti-cancer compounds
Inventor: RALPH STEPHEN JOHN
IPC: A61K31/355
Filed: 2009-03-16
Abstract: Patent No. 602579 Disclosed is a compound for inducing the death of a cancerous cell or for preventing or treating cancer, said compound comprising: a pro-oxidant moiety for (i) generating reactive oxygen species within mitochondria of a cancerous cell, (ii) inducing apoptosis of the cancerous cell, and (iii) interacting with mitochondrial complex II of the cancerous cell, wherein the pro-oxidant moiety comprises a vitamin E analogue comprising a functional domain at position C6 of a substituted chromanol ring that is capable of interacting with a Qp ubiquinone binding site of mitochondrial complex II, a domain that includes the substituted chromanol ring, and a hydrophobic domain comprising at least a seven-carbon long aliphatic chain; and a delivery moiety for delivering the pro-oxidant moiety to the mitochondria of the cancerous cell and for correctly positioning the functional domain for interaction with the Qp ubiquinone binding site, wherein the delivery moiety comprises a delocalized lipophilic cation bound to the aliphatic chain.
Patent NZ-602686-A (NZ)
Title: Prefabricated Building Panel with an inner liner that acts as a bracing element
Inventor: THOMPSON RAYMOND COLIN
IPC: E04C2/00
Filed: 2012-09-27
Abstract: A prefabricated building panel which includes a frame 5 formed within a controlled fabrication environment, and an inner liner material 7 applied to one side of the frame, the inner liner material 7 being applied to the frame 5 using the automated application of fasteners within the controlled fabrication environment, where the inner liner material 7 provides a bracing element of the building panel.
Patent NZ-608207-A (NZ)
Title: Breast cancer therapeutics
Inventor: PENNINGER JOSEF
IPC: A61K39/00
Filed: 2011-09-22
Abstract: Disclosed is the use of a RANKL inhibitor for the manufacture of a medicament for preventing a primary breast or mammary cancer in a subject, wherein the medicament is intended to be administered in a therapeutically effective amount to said subject, wherein said inhibitor inhibits binding of RANKL to RANK.